Optimal Use of BTK Inhibitors in B-Cell Malignancies: Perspectives for the Healthcare Team

Optimal Use of BTK Inhibitors in B-Cell Malignancies: Perspectives for the Healthcare Team

Friday, January 25, 2019 in Lansing, MI
Live Meeting -- Michigan State University Hematology/Oncology Fellowship Program, 7:30 AM ET
McLaren Greater Lansing Women and Children's Center, Conference Room, 2nd Floor

Agenda

Overview on the Role of BTK in Tumor Development

  • BTK signaling pathway
  • Mechanisms of action and properties of available BTK inhibitors
    • Ibrutinib
    • Acalabrutinib

Ibrutinib

  • Clinical development and available data
  • Identifying and managing treatment-related adverse events
  • Ibrutinib resistance mechanisms

Acalabrutinib

  • Clinical development and available data
  • Safety profile compared with ibrutinib

Case Discussions: The Current Clinical Landscape for BTK Inhibitors

  • Mantle cell lymphoma case
  • Chronic lymphocytic leukemia case

Future Directions

  • BTK inhibitor–based combinations
  • Other next-generation BTK inhibitors in clinical development

Closing Remarks and Question and Answer Session

Faculty

CME

Program Overview
Experts present optimal treatment strategies using BTK inhibitors for patients with B-cell malignancies in an interactive 1-hour live workshop at cancer treatment centers across the United States, with a Webcast and affiliated slideset.

Goal Statement
The goal of this activity is to improve participants’ competence in using BTK inhibitors to improve treatment outcomes for patients with mantle cell lymphoma, chronic lymphocytic leukemia, or Waldenström’s macroglobulinemia.

Target Audience 
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with mantle cell lymphoma, chronic lymphocytic leukemia, or Waldenström’s macroglobulinemia.

Learning Objectives 

  • Compare and contrast efficacy and adverse event profiles of the available and emerging BTK inhibitors for the treatment of B-cell malignancies
  • Plan optimal therapeutic strategies for patients with MCL, CLL, and WM
  • Explain to patients the importance of and provide strategies for optimal adherence to prescribed oral therapies
  • Apply multidisciplinary treatment decision making for patients with B-cell malignancies

Accreditation

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Clinical Care Options, LLC. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Purdue University College of Pharmacy designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement
Purdue University Continuing Nursing Education is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is approved for 1.0 contact hour.

Pharmacist Continuing Education

Accreditation Statement
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN) 0018-9999-18-112-L01-P. 1.0 contact hour (0.1 CEU) 

Disclosure of Conflicts of Interest
All faculty, staff, and reviewers involved in the planning, review, or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.